Evidence map›Paper›PMID 30191505›Full record

ArticleHead and neck pathology2019

Interleukin-6/STAT3 Signaling is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell Carcinoma.

Gregory B Lesinski, Sreenivas Nannapaneni, Christopher C Griffith, Mihir Patel, Wanqi Chen, Zhengjia Chen, Rafi Ahmed, Andreas Wieland, Dong M Shin, Zhuo G Chen and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Head and neck pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment.International journal of molecular sciences · 2021
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Gregory B LesinskiDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Rd., NE, Atlanta, GA, 30322, USA.
Sreenivas NannapaneniDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Rd., NE, Atlanta, GA, 30322, USA.
Christopher C GriffithDepartment of Pathology, Winship Cancer Institute of Emory University, Atlanta, USA.
Mihir PatelDepartment of Otolaryngology, Emory University School of Medicine, Atlanta, USA.
Wanqi ChenBiostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, USA.
Zhengjia ChenBiostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, USA.
Rafi AhmedEmory Vaccine Center, Emory University, Atlanta, USA.
Andreas WielandEmory Vaccine Center, Emory University, Atlanta, USA.
Dong M ShinDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Rd., NE, Atlanta, GA, 30322, USA. dmshin@emory.edu.
Zhuo G ChenDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Rd., NE, Atlanta, GA, 30322, USA.
Nabil F SabaDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Rd., NE, Atlanta, GA, 30322, USA. nfsaba@emory.edu.
Emory University · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Enhancing immune therapy in pancreatic cancer by targeting IL-6R01CA208253 · NCI · OHIO STATE UNIVERSITY · PI LESINSKI, GREGORY B. · 2016 to 2021
$1.6M
NCI NIH HHS 1R01CA208253-01NCI NIH HHS P30 CA138292NCI NIH HHS P30CA138292NCI NIH HHS R01 CA208253
6 · The paper itself

Abstract

This study addresses the hypothesis that IL-6/STAT3 signaling is of clinical relevance in oropharyngeal squamous cell carcinoma (OPSCC). We evaluated relationships between key components of this pathway in tumors from a unique cohort of n = 59 fully annotated, treatment-naïve patients with OPSCC. The multiplex Opal platform was utilized for immunofluorescence (IF) analysis of tissues to detect IL-6 and phosphorylated STAT3 (pSTAT3), taking into consideration its nuclear versus cytoplasmic localization. Abundant staining for both IL-6 and pSTAT3 was evident in tumor-rich regions of each specimen. IL-6 correlated with cytoplasmic pSTAT3 but not nuclear or total pSTAT3 in this cohort of OPSCC tumors, regardless of p16 status (r = 0.682, p < 0.0001). There was a significant association between increased total pSTAT3, nuclear pSTAT3, cytoplasmic pSTAT3 and IL-6 in p16 negative tumors. Our data indicate STAT3 phosphorylation was a key feature in p16-negative OPSCC tumors. When IL-6 data was stratified by median expression in tumors, there was no association with overall survival. In contrast, both total and nuclear pSTAT3 were significant predictors of poor overall and disease free survival. This strong inverse relationship with overall survival was present in p16 negative tumors for both total and nuclear pSTAT3, but not in p16 positive OPSCC tumors. Together these data indicate that activation of the STAT3 signaling pathway is a marker of p16 negative tumors and relevant to OPSCC prognosis and a potential target for treatment of this more aggressive OPSCC sub-population.

Indexed as

AdultAgedDisease-Free SurvivalFemaleHumansInterleukin-6MaleMiddle AgedOropharyngeal NeoplasmsSignal TransductionSquamous Cell Carcinoma of Head and NeckSTAT3 Transcription FactorIL6 protein, humanInterleukin-6STAT3 protein, humanSTAT3 Transcription FactorCytokinesHead and neck cancerInterleukin-6P16Squamous cell carcinomaSTAT3

Identifiers

PMID30191505
PMCPMC6684688
OpenAlexW2892119432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.